About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Histology Post-Endoscopic Eradication Therapy (EET)

NCT03375060·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Northwestern University

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

\- Patients who have undergone endoscopic eradication therapy and 24hr pH impedance testing as part of standard of care between 2009 and 2014.
\- Individuals who have signed a consent to be part of the Prospective Evaluation of Barrett's Esophagus Study population.

You may not be if

\- Individuals who are not yet adults (infants, children and teenagers), pregnant women and prisoners will be excluded from the study.
\- Patient who were previously unable or unwilling to give consent to the Prospective Evaluation of Barrett's Esophagus Study will be excluded.

The record

StatusCompleted

PhaseNo phase

Taking part65

StartedAug 2017

UpdatedDec 15, 2017

Conditions

Esophageal Reflux Barrett Esophagus

Where1

Northwestern University
Chicago, Illinois, United States

Clareo Health | Histology Post-Endoscopic Eradication Therapy (EET)